Related Experiment Video

Updated: May 14, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Olmesartan-based therapies: an effective way to improve blood pressure control and cardiovascular protection

Alejandro de la Sierra1, Massimo Volpe

  • 1Department of Internal Medicine, Hospital Mútua Terrassa, University of Barcelona, Spain. adelasierra@mutuaterrassa.cat

Journal of Hypertension
|February 8, 2013
PubMed

Insights

Angiotensin-receptor blockers like olmesartan effectively treat hypertension and protect organs. Combination therapies enhance blood pressure control and cardiovascular prevention in hypertensive patients.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Hypertension treatment aims to reduce cardiovascular disease burden.
  • Angiotensin-receptor blockers (ARBs) are effective and well-tolerated first-line antihypertensives.
  • Blocking the renin-angiotensin cascade offers target organ protection and cardiovascular benefits.

Purpose of the Study:

  • To review the efficacy and tolerability of olmesartan and its combinations in hypertension management.
  • To assess the role of olmesartan in organ protection and cardiovascular prevention.

Main Methods:

  • Review of clinical trials examining olmesartan and its fixed-dose combinations.
  • Analysis of data on blood pressure control, organ protection markers, and cardiovascular outcomes.

Main Results:

  • Olmesartan demonstrated effectiveness and good tolerability in organ protection trials.
  • Improvements observed in markers like microinflammation, plaque volume, vascular hypertrophy, and microalbuminuria.
  • Combination therapies (olmesartan with hydrochlorothiazide/amlodipine) improved antihypertensive efficacy without compromising tolerability.

Conclusions:

  • Olmesartan-based treatment strategies, including single-pill combinations, are effective for blood pressure control in most hypertensive patients.
  • This approach may lead to improved cardiovascular disease prevention.

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...